RECOVER is a clinical study for people who are about to start their first treatment for breast cancer. The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.
*Disclaimer Third Parties
All product and company names are trademarks (TM) or registered trademarks (®) of their respective holders. Use of them does not imply any affiliation, approval, license or endorsement by them.